Mobocertinib
Targeted TherapyApproved for: NSCLCBiomarker: EGFR Exon20 Insertion Mobocertinib (EXKIVITY) is the first oral therapy specifically designed for patients with EGFR Exon20 insertion+ NSCLC Related Research News A Multicenter Study on the Efficacy of Immunotherapy in Advanced Lung Cancer PatientsBMS...